NEW YORK, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Saronic Biotechnology, Inc., a U.S. biotechnology company dedicated to developing novel immunotherapeutics for liver cancer, today announces the publication of human validation data supporting the mechanism of action of its lead therapeutic, SBI1997. The research article, titled “Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on their Localization and Tumor Size” was accepted for publication in the Journal of Immunotherapy.
This article describes a correlation between high levels of Foxp3, a protein marker for regulatory T cells, and poor overall survival among patients with resectable hepatocellular carcinoma. Preclinical testing of SBI1997, Saronic Biotechnology’s lead therapeutic, demonstrated a powerful anti-cancer impact and a reduction in the levels of immunosuppressive regulatory T cells in the tumor microenvironment.
Saronic Biotechnology expects to launch a randomized phase I/II clinical trial of SBI1997 in 2016.
For more information, visit PubMed.gov: “Prognostic Role of Immune Cells in Hepatitis B-associated Hepatocellular Carcinoma Following Surgical Resection Depends on their Localization and Tumor Size” Journal of Immunotherapy, January 2016 – Volume 29 - Issue 1: pages 36-44. http://www.ncbi.nlm.nih.gov/pubmed/26641260
About Saronic Biotechnology, Inc.:
Saronic Biotechnology, Inc. is a preclinical and clinical-stage drug development company established to bring novel immunotherapeutics to clinical use for patients with liver cancer. Founded in New York City by a dedicated team of physicians and scientists with broad expertise in oncology and immunology, Saronic Biotechnology developed its lead product SBI1997, an immunotherapy for hepatocellular carcinoma (HCC). In addition to its innovative clinical program, Saronic Biotechnology has also created a streamlined research pipeline to develop additional therapeutics for launch into phase I clinical trials.
About SBI1997 Therapy:
SBI1997 is an autologous dendritic cell immunotherapy for hepatocellular carcinoma developed by Saronic Biotechnology’s dedicated team of cancer scientists and immunologists. A personalized therapeutic, SBI1997 primes each patient’s immune system to recognize tumor-specific antigens and destroy malignant cells that may emerge after surgery, thereby inhibiting cancer recurrence. In a preclinical model of hepatocellular carcinoma, SBI1997 demonstrated dramatic efficacy in stimulating tumor regression and extending overall survival.
With the exception of cited historical data, this press release includes predictive statements, which represent Saronic Biotechnology’s current expectations of future events. Statements describing objectives and expectations involve risks and uncertainties, which may cause results to differ from statements included herein. Risks and uncertainties include but are not limited to: Company’s ability to raise funds necessary to initiate and maintain operations and regulatory approvals by federal and institutional entities.
Contact: Leslie Warren email@example.com
Source:Saronic Biotechnology, Inc.